Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Share-based Compensation: 2014-2025

Historic Share-based Compensation for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to $7.3 million.

  • Viking Therapeutics' Share-based Compensation fell 18.33% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.9 million, marking a year-over-year increase of 34.75%. This contributed to the annual value of $29.7 million for FY2024, which is 77.39% up from last year.
  • Per Viking Therapeutics' latest filing, its Share-based Compensation stood at $7.3 million for Q3 2025, which was down 45.85% from $13.5 million recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Share-based Compensation ranged from a high of $13.5 million in Q2 2025 and a low of $1.4 million during Q4 2021.
  • Over the past 3 years, Viking Therapeutics' median Share-based Compensation value was $7.1 million (recorded in 2024), while the average stood at $7.2 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 130.98% in 2023, then dropped by 18.33% in 2025.
  • Over the past 5 years, Viking Therapeutics' Share-based Compensation (Quarterly) stood at $1.4 million in 2021, then spiked by 50.45% to $2.2 million in 2022, then spiked by 89.24% to $4.1 million in 2023, then soared by 38.90% to $5.7 million in 2024, then declined by 18.33% to $7.3 million in 2025.
  • Its Share-based Compensation stands at $7.3 million for Q3 2025, versus $13.5 million for Q2 2025 and $11.3 million for Q1 2025.